Business
Strategic Advisory Board & Appointment of Dir...
Strategic Advisory Board & Appointment of Dir....
About this update from 4basebio Plc
[{"type":"text","content":"\n\n \n \n\n\n\n\n 8 August 2024 4basebio PLC(\"4basebio\" or the \"Company\") Strategic Advisory Board FormationAppointment of Director Cambridge, UK, 8th August 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces the formation of a Strategic Advisory Board and the appointment of Dr Amy Walker, the Vice President of Research and Business Development to the Board of Directors of the Company as Chief Operating Officer.Strategic Advisory BoardEffective from 1 July 2024, the Company formed a Strategic Advisory Board (“SAB”), with the purpose of offering the Company’s leadership team valuable advice and industry insight spanning technical, operational, commercial and strategic matters as well as supporting the Company in the realisation of its growth goals and objectives. The SAB advisers are engaged for an initial period of 12 months from its formation and will meet with the leadership team periodically. The SAB comprises the following experts:Bertrand Coissac, CEO at Twogene: Mr. Coissac has extensive experience in the life science industry with a focus on cell and gene therapy manufacturing. Before co-founding and leading Twogene, Mr. Coissac was Vice President of Corporate Development at Polyplus which was successfully acquired by Sartorius in July 2023.Lawrence Pitcher, VP at Catalent Pharma Solutions: Mr. Pitcher is currently the Vice President and General Manager, Maryland Gene Therapy Sites at Catalent Pharma Solutions. He brings significant operational and business experience from his current Catalent role and previous roles at Thermo Fisher Scientific where he was most recently the General Manager of the Advance Therapies business. Deborah Barbara, Former Vice President at Maravai Life Sciences: Ms. Barbara has over 30 years of life science industry experience in a variety of strategic business and corporate development roles, most recently as Vice President of Strategy and Corporate Development for Maravai Life Sciences. Prior to joining Maravai, Ms. Barbara was General Manager of Nucleic Acid Therapeutics business for Thermo Fisher Scientific. Appointment of DirectorIn addition to the above, the Company announces the appointment of Dr Amy Walker as Chief Operating...